Biogen no longer under investigation by EU over MS drug patent move
By Lewis Crofts ( July 20, 2026, 12:28 GMT | Insight) -- Biogen is no longer under investigation by the European Commission for a potential antitrust breach over extra patent protection related to a multiple sclerosis drug, MLex has learned. The US company had received questions from EU officials in January over concerns related to a "divisional" patent. Biogen is no longer under investigation by the European Commission for a potential antitrust breach from extra patent protection related to a multiple sclerosis drug, MLex has learned....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.